| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of US$ 1/kg
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Pharmaceutical Grade API Castration-Resistant Prostate Cancer Cabazitaxel Anti-Cancer Cabazitaxel
| Product name:Cabazitaxel Powder |
| Other Name: Cabazitaxel; XRP-6258;TXD 258;7β,10β-Dimethoxydocetaxel |
| Appearance:White Powder |
| CAS:183133-96-2 |
| M.F:C45H57NO14 |
| M.W.:835.93 |
| Specification:99% |
Cabazitaxel (previously XRP-6258) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Cabazitaxel in combination is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
Cabazitaxel anticancer mechanism and characteristics similar with docetaxel, belongs to anti-microtubule drugs. Cabazitaxel through binding to tubulin, promoting their assembly into microtubules, and can prevent these have assembled a microtubule disintegration of the stabilization of microtubules, thereby inhibiting cell mitosis, and interphase cellular functions (interphasecellularfunctions) of play.
Related Product
| Product Name | CAS No. | Product Name | CAS No. |
| Lufenuron | 103055-07-8 | Toltrazuril | 69004-03-1 |
| Nitenpyram | 120738-89-8 | Praziquantel/Biltricide | 55268-74-1 |
| Fenbendazole | 43210-67-9 | Tetramisole Hcl | 5086-74-8 |
| Levamisole | 14769-73-4 | Ponazuril | 9004-4-2 |
| Diclazuril | 101831-37-2 | Florfenicol | 73231-34-2 |
| Ivermectin | 70288-86-7 | Enrofloxacin Hcl | 112732-17-9 |
| Albendazole | 54965-21-8 | Mebendazole | 31431-39-7 |
| ITEM | SPECIFICATION | RESULT | METHOD |
| Appearance | White powder, neutral odor, highly hygroscopic | Conforms | Visual |
| Identification | Standard solution and test solution same spot,RF | Conforms | TLC |
| Specific Optical | -2.4°~ -2.8° | -2.72° | |
| Heavy metals (as PB) | ≤10ppm | Conforms | AAS |
| Sulfate (SO4) | ≤0.02% | Conforms | Colorimetry |
| Chloride (Cl) | ≤0.02% | Conforms | Colorimetry |
| Phosphate Ion (P) | ≤5ppm | Conforms | Colorimetry |
| Residual solvent(ethanol) | ≤1.0% | Conforms | HS-GC |
| pH | 4.5~7.0 | 5.10 | |
| Related substance | Spot not bigger than standard solution spot | No spot | TLC |
| Water Content | ≤2% | 0.26% | KF |
| Assay (dried basis) | 98.0%--102.0% | 99.48% | Potentiometric titration |
| Assay (dried basis) | 98.5%--100% | 99.2% | HPLC |
Function:
Cabazitaxel's anti-cancer mechanism and characteristics are similar to docetaxel and belong to anti-microtubule drugs. Cabazitaxel promotes its assembly into microtubules by binding to tubulin, while preventing the disassembly of these assembled microtubules, stabilizing microtubules, thereby inhibiting cell mitosis, and interphase cellular functions.
){kind=link}